奥马佐单抗
医学
哮喘
中耳炎
免疫球蛋白E
嗜酸性
算法
儿科
内科学
免疫学
抗体
外科
病理
计算机科学
作者
Azusa Okude,Etsuko Tagaya,Mitsuko Kondo,Manabu Nonaka,Jun Tamaoki
摘要
A 51-year-old woman had been receiving medical treatment for asthma since she was 21 years old. However, her asthma was poorly controlled despite treatment involving combination inhalation of high-dose corticosteroid and long-actingβ2-aderenergic agonist (LABA) and regularly taking oral steroids. Hearing loss and otorrhea appeared at the age of 44, and she was given a diagnosis of eosinophilic otitis media (EOM) and received medical treatment. In 2007, symptoms of asthma and otitis media deteriorated. In December 2009, omalizumab therapy was started for refractory asthma. After 2 months of omalizumab treatment, not only asthma, but also hearing loss improved. It is suggested that early initiation of omalizumab therapy may inhibit the progression of progressive EOM.
科研通智能强力驱动
Strongly Powered by AbleSci AI